secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sarepta Therapeutics, Inc. (SRPT)
CIK:        0000873303
Form:       8-K
Filed at:   2023-06-22T23:59:59+00:00
Accession:  0000950170-23-029438
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sarepta sets wholesale acquisition cost for ELEVIDYS at $3.2 million
--------------------------------------------------------------------

- Wholesale acquisition cost (gross price) of gene therapy ELEVIDYS set at $3.2 million.
- Indicated for ambulatory pediatric patients aged 4-5 years with DMD gene mutation.
- Price disclosed during investor webcast on June 22, 2023.
- NASDAQ ticker: SRPT.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/873303/000095017023029438/0000950170-23-029438-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/873303/000095017023029438/srpt-20230622.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-029438

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer